Boston Scientific’s Agent DCB: Strong Early Adoption and Underappreciated Multiyear Growth Opportunity

TD Cowen analyst Josh Jennings maintained a Buy rating on Boston Scientific today and set a price target of $100.00.

Josh Jennings has given his Buy rating due to a combination of factors, starting with the strong early adoption of Boston Scientific’s Agent drug‑coated balloon in U.S. in‑stent restenosis procedures, where it has quickly captured a meaningful share of a market that was historically dominated by stents and plain balloons. This rapid uptake has already helped accelerate growth in the company’s broader drug‑eluting technology franchise, signaling that Agent is emerging as an important growth driver rather than a niche product.

Jennings also points to the supportive clinical experience presented at CRT, where real‑world registry data showed broad hospital penetration, expanding procedure volumes, and increasing off‑label use of Agent without a safety penalty versus alternative treatments. Taken together, these trends suggest a multiyear expansion opportunity as Agent moves beyond ISR into de novo coronary lesions, which Jennings believes is not fully reflected in investor expectations and underpins his positive stance on BSX shares.

In another report released yesterday, Jefferies also maintained a Buy rating on the stock with a $120.00 price target.